Roche, Zealand Ink $5.3 Billion Obesity Drug Licensing Deal

Roche has entered a $5.3 billion licensing deal with Zealand Pharma to co-develop and co-commercialize petrelintide, an amylin analog for obesity treatment. The agreement includes an upfront payment of $1.65 billion, with additional milestone payments linked to the drug's development and sales. Petrelintide will be developed as a standalone therapy and in combination with Roche's CT-388, with commercialization rights shared in the U.S. and Europe, and Roche holding exclusive rights elsewhere. This partnership positions Zealand Pharma alongside major weight-loss drug companies like Novo Nordisk and Eli Lilly. The collaboration aims to expand treatment options in the growing obesity market, leveraging Roche's expertise and Zealand's innovative approach. The deal is expected to close in the second quarter of 2025.